Biomimetic Gold for Biotherapy

$40.00

Biomimetic Gold for Biotherapy

S.Z.Z.Cobongela, N.R.S Sibuyi, Maha Khan

Biomimetic gold nanomaterials (AuNMs) present a promising class of nano-biotherapeutic agents with potential across a range of biomedical applications due to their unique properties. They exhibit tunable physicochemical properties, biocompatibility, and structural versatility, making them ideal candidates for the development of novel therapies. Functionalising AuNMs with active pharmaceutical ingredients and biomolecules significantly enhances their therapeutic potential against communicable and non-communicable diseases. Conjugation of disease-specific biologics to AuNMs enables precise targeting, improves selectivity, enhances intracellular uptake, and reduces off-target effects, thus promoting therapeutic efficacy. Oncology-focused studies utilise the strong localized surface plasmon resonance (LSPR) of AuNM for photothermal ablation of various cancer tumours. This chapter highlights the design and functionalization of drug-AuNM hybrids and their possible biotherapeutic applications. Preclinical studies demonstrate translatable research into clinical applications with promising efficacy and safety profiles. It further focuses on advanced biomimetic gold biotherapeutic agents such as CYT-6091, CNM-Au8, and others, currently in clinical development with promising safety and efficacy for targeted disease treatment.

Keywords
Biomimetic, Aunm, LSPR, Nano-Based, Therapy, Efficacy, Functionalisation, Tumour

Published online , 17 pages

Citation: S.Z.Z.Cobongela, N.R.S Sibuyi, Maha Khan, Biomimetic Gold for Biotherapy, Materials Research Foundations, Vol. 193, pp 200-216, 2026

DOI: https://doi.org/10.21741/9781644904350-9

Part of the book on Biomimetic

References
[1] H. Moustaoui, D. Movia, N. Dupont, N. Bouchemal, S. Casale, N. Djaker, P. Savarin, A. Prina-Mello, M.L. de la Chapelle, J. Spadavecchia, Tunable design of gold(iii)-doxorubicin complex-pegylated nanocarrier. The golden doxorubicin for oncological applications, ACS Appl Mater Interfaces 8 (2016) 19946-19957. https://doi.org/10.1021/acsami.6b07250
[2] J. Spadavecchia, D. Movia, C. Moore, C.M. Maguire, H. Moustaoui, S. Casale, Y. Volkov, A. Prina-Mello, Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: From synthesis to proof-of-concept in vitro studies, Int J Nanomedicine 11 (2016) 791-822. https://doi.org/10.2147/IJN.S97476
[3] J.W. Kang, H.J. Cho, H.J. Lee, H.E. Jin, H.J. Maeng, Polyethylene glycol-decorated doxorubicin/carboxymethyl chitosan/gold nanocomplex for reducing drug efflux in cancer cells and extending circulation in bloodstream, Int J Biol Macromol 125 (2019) 61-71. https://doi.org/10.1016/j.ijbiomac.2018.12.028
[4] N.S. Elbialy, M.M. Fathy, W.M. Khalil, Preparation and characterization of magnetic gold nanoparticles to be used as doxorubicin nanocarriers, Phys Med 30 (2014) 843-848. https://doi.org/10.1016/j.ejmp.2014.05.012
[5] C. Barbey, N. Bouchemal, P. Retailleau, N. Dupont, J. Spadavecchia, Idarubicin-gold complex: From crystal growth to gold nanoparticles, ACS Omega 6 (2021) 1235-1245. https://doi.org/10.1021/acsomega.0c04501
[6] G.M. Luz, J.F. Mano, Biomimetic design of materials and biomaterials inspired by the structure of nacre, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences 367 (2009) 1587-1605. https://doi.org/10.1098/rsta.2009.0007
[7] C. Arib, J. Spadavecchia, M.L. de la Chapelle, Enzyme-mediated synthesis of hybrid polyedric gold nanoparticles, Sci Rep 11 (2021) 3208. https://doi.org/10.1038/s41598-021-81751-1
[8] C. Garcia-Hernandez, A.K. Freese, M.L. Rodriguez-Mendez, A.K. Wanekaya, In situ synthesis, stabilization and activity of protein-modified gold nanoparticles for biological applications, Biomater. Sci. 7 (2019) 2511-2519. https://doi.org/10.1039/C9BM00129H
[9] G. Das, S. Seo, I.J. Yang, L.T.H. Nguyen, H.S. Shin, J.K. Patra, Synthesis of biogenic gold nanoparticles by using sericin protein from bombyx mori silk cocoon and investigation of its wound healing, antioxidant, and antibacterial potentials, IJN 18 (2023) 17-34. https://doi.org/10.2147/IJN.S378806
[10] Y. Yue, Y. Yokota, T. Uchihashi, Biosynthesis of highly branched gold nanoparticles through structural engineering of fatty acids, iScience 26 (2022) 105864. https://doi.org/10.1016/j.isci.2022.105864
[11] A.S. Schwartz-Duval, R. Wen, I. Srivastava, P. Moitra, D. Pan, A simplistic single-step method for preparing biomimetic nanoparticles from endogenous biomaterials, ACS Appl. Mater. Interfaces 13 (2021) 46464-46477. https://doi.org/10.1021/acsami.1c17302
[12] E.O. Mikhailova, Gold nanoparticles: Biosynthesis and potential of biomedical application, J Funct Biomater 12 (2021) 70. https://doi.org/10.3390/jfb12040070
[13] A. Nyabadza, É. McCarthy, M. Makhesana, S. Heidarinassab, A. Plouze, M. Vazquez, D. Brabazon, A review of physical, chemical and biological synthesis methods of bimetallic nanoparticles and applications in sensing, water treatment, biomedicine, catalysis and hydrogen storage, Advances in Colloid and Interface Science 321 (2023) 103010. https://doi.org/10.1016/j.cis.2023.103010
[14] V. Šubr, L. Kostka, J. Plicka, O. Sedláček, T. Etrych, Highly effective synthetic polymer-based blockers of non-specific interactions in immunochemical analyses, Polymers (Basel) 16 (2024) 758. https://doi.org/10.3390/polym16060758
[15] R. Ahirwar, S. Bariar, A. Balakrishnan, P. Nahar, BSA blocking in enzyme-linked immunosorbent assays is a non-mandatory step: A perspective study on the mechanism of BSA blocking in common ELISA protocols, RSC Adv. 5 (2015) 100077-100083. https://doi.org/10.1039/C5RA20750A
[16] J.T. Duskey, F. da Ros, I. Ottonelli, B. Zambelli, M.A. Vandelli, G. Tosi, B. Ruozi, Enzyme stability in nanoparticle preparations part 1: Bovine serum albumin improves enzyme function, Molecules 25 (2020) 4593. https://doi.org/10.3390/molecules25204593
[17] B.T. Doumas, Standards for total serum protein assays-a collaborative study, Clin Chem 21 (1975) 1159-1166. https://doi.org/10.1093/clinchem/21.8.1159
[18] A. Aguilera-Garrido, T. del Castillo-Santaella, Y. Yang, F. Galisteo-González, M.J. Gálvez-Ruiz, J.A. Molina-Bolívar, J.A. Holgado-Terriza, M.Á. Cabrerizo-Vílchez, J. Maldonado-Valderrama, Applications of serum albumins in delivery systems: Differences in interfacial behaviour and interacting abilities with polysaccharides, Advances in Colloid and Interface Science 290 (2021) 102365. https://doi.org/10.1016/j.cis.2021.102365
[19] K. Kulig, B. Morak-Młodawska, M. Jeleń, M. Ziąbka, A. Owczarzy, W. Rogóż, M. Maciążek-Jurczyk, Bovine serum albumin nanoparticles as a proposed drug formulation for the delivery of 10H-2,7-diazaphenothiazine, J Clust Sci 35 (2024) 2353-2362. https://doi.org/10.1007/s10876-024-02666-1
[20] C. Fu, C. Ding, X. Sun, A. Fu, Curcumin nanocapsules stabilized by bovine serum albumin-capped gold nanoclusters (BSA-AuNCs) for drug delivery and theranosis, Materials Science and Engineering: C 87 (2018) 149-154. https://doi.org/10.1016/j.msec.2017.12.028
[21] Z. Kayani, O. Firuzi, A.-K. Bordbar, Doughnut-shaped bovine serum albumin nanoparticles loaded with doxorubicin for overcoming multidrug-resistant in cancer cells, International Journal of Biological Macromolecules 107 (2018) 1835-1843. https://doi.org/10.1016/j.ijbiomac.2017.10.041
[22] S. Fuloria, J. Mehta, A. Chandel, M. Sekar, N.N.I.M. Rani, M.Y. Begum, V. Subramaniyan, K. Chidambaram, L. Thangavelu, R. Nordin, Y.S. Wu, K.V. Sathasivam, P.T. Lum, D.U. Meenakshi, V. Kumarasamy, A.K. Azad, N.K. Fuloria, A comprehensive review on the therapeutic potential of curcuma longa linn. in relation to its major active constituent curcumin, Front. Pharmacol. 13 (2022). https://doi.org/10.3389/fphar.2022.820806
[23] G. Flora, D. Gupta, A. Tiwari, Nanocurcumin: A promising therapeutic advancement over native curcumin, Crit Rev Ther Drug Carrier Syst 30 (2013) 331-368. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2013007236
[24] M. Lv, Q. Sun, Y. Yu, J. Bao, Nanocurcumin in myocardial infarction therapy: Emerging trends and future directions, Front. Bioeng. Biotechnol. 12 (2025). https://doi.org/10.3389/fbioe.2024.1511331
[25] M. boroughani, A.K. Moaveni, P. Hatami, N. Mansoob Abasi, S.A. Seyedoshohadaei, A. Pooladi, Y. Moradi, R. Rahimi Darehbagh, Nanocurcumin in cancer treatment: A comprehensive systematic review, Discov Onc 15 (2024) 515. https://doi.org/10.1007/s12672-024-01272-x
[26] R. Khandelia, S. Bhandari, U.N. Pan, S.S. Ghosh, A. Chattopadhyay, Gold nanocluster embedded albumin nanoparticles for two-photon imaging of cancer cells accompanying drug delivery, Small 11 (2015) 4075-4081. https://doi.org/10.1002/smll.201500216
[27] R. Solanki, H. Rostamabadi, S. Patel, S.M. Jafari, Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: A critical review, Int J Biol Macromol 193 (2021) 528-540. https://doi.org/10.1016/j.ijbiomac.2021.10.040
[28] M.M. Mamun, A.J. Sorinolu, M. Munir, E.P. Vejerano, Nanoantibiotics: Functions and properties at the nanoscale to combat antibiotic resistance, Front. Chem. 9 (2021) 687660. https://doi.org/10.3389/fchem.2021.687660
[29] C. Mutalik, M. Saukani, M. Khafid, D.I. Krisnawati, Widodo, R. Darmayanti, B. Puspitasari, T.-M. Cheng, T.R. Kuo, Gold-based nanostructures for antibacterial application, Int J Mol Sci 24 (2023) 10006. https://doi.org/10.3390/ijms241210006
[30] F.I. Maier, D. Klinger, M. Grieshober, R. Noschka, A. Rodriguez, S. Wiese, W.G. Forssmann, L. Ständker, S. Stenger, Lysozyme: An endogenous antimicrobial protein with potent activity against extracellular, but not intracellular Mycobacterium tuberculosis, Med Microbiol Immunol 213 (2024) 9. https://doi.org/10.1007/s00430-024-00793-0
[31] N. Nawaz, S. Wen, F. Wang, S. Nawaz, J. Raza, M. Iftikhar, M. Usman, Lysozyme and its application as antibacterial agent in food industry, Molecules 27 (2022) 6305. https://doi.org/10.3390/molecules27196305
[32] Y. Zhang, H. Yan, R. Su, P. Li, F. Wen, Y. Lv, J. Cai, W. Su, Photoactivated multifunctional nanoplatform based on lysozyme-Au nanoclusters-curcumin conjugates with FRET effect and multiamplified antimicrobial activity, Journal of Drug Delivery Science and Technology 74 (2022) 103548. https://doi.org/10.1016/j.jddst.2022.103548
[33] Y. Zou, R. Xie, E. Hu, P. Qian, B. Lu, G. Lan, F. Lu, Protein-reduced gold nanoparticles mixed with gentamicin sulfate and loaded into konjac/gelatin sponge heal wounds and kill drug-resistant bacteria, International Journal of Biological Macromolecules 148 (2020) 921-931. https://doi.org/10.1016/j.ijbiomac.2020.01.190
[34] O. Akturk, K. Kismet, A.C. Yasti, S. Kuru, M.E. Duymus, F. Kaya, M. Caydere, S. Hucumenoglu, D. Keskin, Collagen/gold nanoparticle nanocomposites: A potential skin wound healing biomaterial, J Biomater Appl 31 (2016) 283-301. https://doi.org/10.1177/0885328216644536
[35] S. Guerrero, E. Araya, J.L. Fiedler, J.I. Arias, C. Adura, F. Albericio, E. Giralt, J.L. Arias, M.S. Fernández, M.J. Kogan, Improving the brain delivery of gold nanoparticles by conjugation with an amphipathic peptide, Nanomedicine (Lond) 5 (2010) 897-913. https://doi.org/10.2217/nnm.10.74
[36] M. Shilo, M. Motiei, P. Hana, R. Popovtzer, Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications, Nanoscale 6 (2014) 2146-2152. https://doi.org/10.1039/C3NR04878K
[37] S. Guerrero, J.R. Herance, S. Rojas, J.F. Mena, J.D. Gispert, G.A. Acosta, F. Albericio, M.J. Kogan, Synthesis and in vivo evaluation of the biodistribution of an 18F-labeled conjugate gold-nanoparticle-peptide with potential biomedical application, Bioconjug Chem 23 (2012) 399-408. https://doi.org/10.1021/bc200362a
[38] R. Prades, S. Guerrero, E. Araya, C. Molina, E. Salas, E. Zurita, J. Selva, G. Egea, C. López-Iglesias, M. Teixidó, M.J. Kogan, E. Giralt, Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor, Biomaterials 33 (2012) 7194-7205. https://doi.org/10.1016/j.biomaterials.2012.06.063
[39] S. Farhangi, E. Karimi, K. Khajeh, S. Hosseinkhani, M. Javan, Peptide-mediated targeted delivery of gold nanoparticles into the demyelination site ameliorates myelin impairment and gliosis, Nanomedicine: Nanotechnology, Biology and Medicine 47 (2023) 102609. https://doi.org/10.1016/j.nano.2022.102609
[40] S. Ahmed, A.S. Mathews, N. Byeon, A. Lavasanifar, K. Kaur, Peptide arrays for screening cancer-specific peptides, Anal Chem 82 (2010) 7533-7541. https://doi.org/10.1021/ac1003085
[41] R. Soudy, A. Gill, T. Sprules, A. Lavasanifar, K. Kaur, Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells, J Med Chem 54 (2011) 7523-7534. https://doi.org/10.1021/jm200750x
[42] B.F. Craciun, L. Clima, D.-I. Bostiog, M. Silion, M. Calin, D. Peptanariu, M. Pinteala, Multilayer gold nanoparticles as non-viral vectors for targeting MCF-7 cancer cells, Biomaterials Advances 144 (2023) 213201. https://doi.org/10.1016/j.bioadv.2022.213201
[43] H. Groult, J. Ruiz-Cabello, J. Pellico, A.V. Lechuga-Vieco, R. Bhavesh, M. Zamai, E. Almarza, I. Martín-Padura, E. Cantelar, M.P. Martínez-Alcázar, F. Herranz, Parallel multifunctionalization of nanoparticles: A one-step modular approach for in vivo imaging, Bioconjug Chem 26 (2015) 153-160. https://doi.org/10.1021/bc500536y
[44] H. Javid, M.A. Oryani, N. Rezagholinejad, A. Esparham, M. Tajaldini, M. Karimi‐Shahri, RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions, Cancer Med 13 (2024) e6800. https://doi.org/10.1002/cam4.6800
[45] C. Yang, J. Uertz, D.B. Chithrani, Colloidal gold-mediated delivery of bleomycin for improved outcome in chemotherapy, Nanomaterials 6 (2016) 48. https://doi.org/10.3390/nano6030048
[46] M. Luna-Gutiérrez, G. Ferro-Flores, B.E. Ocampo-García, C.L.S.- Cuevas, N. Jiménez-Mancilla, L.M.D. León-Rodríguez, E. Azorín-Vega, K.I.- Olivé, A therapeutic system of 177Lu-labeled gold nanoparticles-RGD internalized in breast cancer cells, Journal of the Mexican Chemical Society 57 (2013) 212-219. https://doi.org/10.29356/jmcs.v57i3.209
[47] A. Vilchis-Juárez, G. Ferro-Flores, C. Santos-Cuevas, E. Morales-Avila, B. Ocampo-García, L. Díaz-Nieto, M. Luna-Gutiérrez, N. Jiménez-Mancilla, M. Pedraza-López, L. Gómez-Oliván, Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice, J Biomed Nanotechnol 10 (2014) 393-404. https://doi.org/10.1166/jbn.2014.1721
[48] S. Gera, E. Kankuri, K. Kogermann, Antimicrobial peptides – Unleashing their therapeutic potential using nanotechnology, Pharmacology & Therapeutics 232 (2022) 107990. https://doi.org/10.1016/j.pharmthera.2021.107990
[49] U. Anand, A. Dey, A.K.S. Chandel, R. Sanyal, A. Mishra, D.K. Pandey, V. De Falco, A. Upadhyay, R. Kandimalla, A. Chaudhary, J.K. Dhanjal, S. Dewanjee, J. Vallamkondu, J.M. Pérez de la Lastra, Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics, Genes Dis 10 (2022) 1367-1401. https://doi.org/10.1016/j.gendis.2022.02.007
[50] V.P. Chauhan, R.K. Jain, Strategies for advancing cancer nanomedicine, Nature Mater 12 (2013) 958-962. https://doi.org/10.1038/nmat3792
[51] S. Jia, C. Bian, J. Sun, J. Tong, S. Xia, A wavelength-modulated localized surface plasmon resonance (LSPR) optical fiber sensor for sensitive detection of mercury (II) ion by gold nanoparticles-DNA conjugates, Biosens Bioelectron 114 (2018) 15-21. https://doi.org/10.1016/j.bios.2018.05.004
[52] V.D. Matteis, L. Rizzello, M. Cascione, E. Liatsi-Douvitsa, A. Apriceno, Green plasmonic nanoparticles and bio-inspired stimuli-responsive vesicles in cancer therapy application, Nanomaterials (Basel) 10 (2020) 1083. https://doi.org/10.3390/nano10061083
[53] S. Huang, J. Chen, T. Zhang, X. Dai, X. Wang, J. Zhou, W. Kong, Q. Liu, J. Qu, Y. Shao, Recent advances in surface plasmon resonance microscopy, Chemosensors 10 (2022) 509. https://doi.org/10.3390/chemosensors10120509
[54] M.P. Mcoyi, K.T. Mpofu, M. Sekhwama, P. Mthunzi-Kufa, Developments in localized surface plasmon resonance, Plasmonics 20 (2024) 5481-5520. https://doi.org/10.1007/s11468-024-02620-x
[55] S. Adhikari, P. Spaeth, A. Kar, M.D. Baaske, S. Khatua, M. Orrit, Photothermal microscopy: Imaging the optical absorption of single nanoparticles and single molecules, ACS Nano 14 (2020) 16414-16445. https://doi.org/10.1021/acsnano.0c07638
[56] L. Guidi, M.G. Cascone, E. Rosellini, Light-responsive polymeric nanoparticles for retinal drug delivery: Design cues, challenges and future perspectives, Heliyon 10 (2024) e26616. https://doi.org/10.1016/j.heliyon.2024.e26616
[57] H. Kim, V.P. Nguyen, P. Manivasagan, M.J. Jung, S.W. Kim, J. Oh, H.W. Kang, Doxorubicin-fucoidan-gold nanoparticles composite for dualchemo-photothermal treatment on eye tumors, Oncotarget 8 (2017) 113719-113733. https://doi.org/10.18632/oncotarget.23092
[58] C.-S. Lee, H. Kim, J. Yu, S.H. Yu, S. Ban, S. Oh, D. Jeong, J. Im, M.J. Baek, T.H. Kim, Doxorubicin-loaded oligonucleotide conjugated gold nanoparticles: A promising in vivo drug delivery system for colorectal cancer therapy, European Journal of Medicinal Chemistry 142 (2017) 416-423. https://doi.org/10.1016/j.ejmech.2017.08.063
[59] S. Mocellin, C.R. Rossi, P. Pilati, D. Nitti, Tumor necrosis factor, cancer and anticancer therapy, Cytokine Growth Factor Rev 16 (2005) 35-53. https://doi.org/10.1016/j.cytogfr.2004.11.001
[60] S.K. Libutti, G.F. Paciotti, A.A. Byrnes, H.R. Alexander, W.E. Gannon, M. Walker, G.D. Seidel, N. Yuldasheva, L. Tamarkin, Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine, Clin Cancer Res 16 (2010) 6139-6149. https://doi.org/10.1158/1078-0432.CCR-10-0978
[61] G.F. Paciotti, L. Myer, D. Weinreich, D. Goia, N. Pavel, R.E. McLaughlin, L. Tamarkin, Colloidal gold: A novel nanoparticle vector for tumor-directed drug delivery, Drug Deliv 11 (2004) 169-183. https://doi.org/10.1080/10717540490433895
[62] R. Goel, N. Shah, R. Visaria, G.F. Paciotti, J.C. Bischof, Biodistribution of TNF-α-coated gold nanoparticles in an in vivo model system, Nanomedicine (Lond) 4 (2009) 401-410. https://doi.org/10.2217/nnm.09.21
[63] National Institutes of Health Clinical Center (CC), A Phase I Trial of TNF-Bound Colloidal Gold (CYT-6091) by Intravenous Administration in Subjects with Advanced Solid Organ Malignancies, clinicaltrials.gov, 2012. https://clinicaltrials.gov/study/NCT00356980 (accessed June 28, 2025).
[64] S.K. Libutti, G.F. Paciotti, A.A. Byrnes, H.R. Alexander, W.E. Gannon, M. Walker, G.D. Seidel, N. Yuldasheva, L. Tamarkin, Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine, Clin Cancer Res 16 (2010) 6139-6149. https://doi.org/10.1158/1078-0432.CCR-10-0978
[65] National Institutes of Health Clinical Center (CC), An Evaluation of the Tissue Distribution and the Selective Tumor Trafficking of TNF-Bound Colloidal Gold (CYT-6091) Following Intravenous Administration in Subjects with Primary and Metastatic Cancer Undergoing Surgical Resection, clinicaltrials.gov, 2012. https://clinicaltrials.gov/study/NCT00436410 (accessed June 28, 2025).
[66] W.-C. Tseng, H.-C. Lai, Y.-H. Huang, S.-M. Chan, Z.-F. Wu, Tumor necrosis factor alpha: Implications of anesthesia on cancers, Cancers (Basel) 15 (2023) 739. https://doi.org/10.3390/cancers15030739
[67] H. Shin, S.-J. Park, Y. Yim, J. Kim, C. Choi, C. Won, D.-H. Min, Recent advances in RNA therapeutics and RNA delivery systems based on nanoparticles, Advanced Therapeutics 1 (2018) 1800065. https://doi.org/10.1002/adtp.201800065
[68] S.A. Jensen, E.S. Day, C.H. Ko, L.A. Hurley, J.P. Luciano, F.M. Kouri, T.J. Merkel, A.J. Luthi, P.C. Patel, J.I. Cutler, W.L. Daniel, A.W. Scott, M.W. Rotz, T.J. Meade, D.A. Giljohann, C.A. Mirkin, A.H. Stegh, Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma, Sci Transl Med 5 (2013) 209ra152. https://doi.org/10.1126/scitranslmed.3006839
[69] P. Kumthekar, A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients, clinicaltrials.gov, 2022. https://clinicaltrials.gov/study/NCT03020017 (accessed June 29, 2025).
[70] P. Kumthekar, C.H. Ko, T. Paunesku, K. Dixit, A.M. Sonabend, O. Bloch, M. Tate, M. Schwartz, L. Zuckerman, R. Lezon, R.V. Lukas, B. Jovanovic, K. McCortney, H. Colman, S. Chen, B. Lai, O. Antipova, J. Deng, L. Li, S. Tommasini-Ghelfi, L.A. Hurley, D. Unruh, N.V. Sharma, M. Kandpal, F.M. Kouri, R.V. Davuluri, D.J. Brat, M. Muzzio, M. Glass, V. Vijayakumar, J. Heidel, F.J. Giles, A.K. Adams, C.D. James, G.E. Woloschak, C. Horbinski, A.H. Stegh, A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent Glioblastoma, Sci Transl Med 13 (2021) eabb3945. https://doi.org/10.1126/scitranslmed.abb3945
[71] P. Kumthekar, C.H. Ko, T. Paunesku, K. Dixit, A.M. Sonabend, O. Bloch, M. Tate, M. Schwartz, L. Zuckerman, R. Lezon, R.V. Lukas, B. Jovanovic, K. McCortney, H. Colman, S. Chen, B. Lai, O. Antipova, J. Deng, L. Li, S. Tommasini-Ghelfi, L.A. Hurley, D. Unruh, N.V. Sharma, M. Kandpal, F.M. Kouri, R.V. Davuluri, D.J. Brat, M. Muzzio, M. Glass, V. Vijayakumar, J. Heidel, F.J. Giles, A.K. Adams, C.D. James, G.E. Woloschak, C. Horbinski, A.H. Stegh, A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent Glioblastoma, Sci Transl Med 13 (2021) eabb3945. https://doi.org/10.1126/scitranslmed.abb3945
[72] D. Tatovic, M.A. McAteer, J. Barry, A. Barrientos, K. Rodríguez Terradillos, I. Perera, E. Kochba, Y. Levin, M. Dul, S.A. Coulman, J.C. Birchall, C. von Ruhland, A. Howell, R. Stenson, M. Alhadj Ali, S.D. Luzio, G. Dunseath, W.Y. Cheung, G. Holland, K. May, J.R. Ingram, M.M.U. Chowdhury, F.S. Wong, R. Casas, C. Dayan, J. Ludvigsson, Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes, Immunother Adv 2 (2022) ltac002. https://doi.org/10.1093/immadv/ltac002
[73] Cardiff University, Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 (EE-ASI-1): A Phase 1a Study of Gold Nanoparticles Administered Intradermally by Microneedles to Deliver Immunotherapy with a Proinsulin Derived Peptide in Type 1 Diabetes, clinicaltrials.gov, 2023. https://clinicaltrials.gov/study/NCT02837094 (accessed June 29, 2025).
[74] S.J. Hanna, T.C. Thayer, E.J.S. Robinson, N.-N. Vinh, N. Williams, L.G. Landry, R. Andrews, Q.Z. Siah, P., Leete, R., Wyatt, M.A., McAteer, M., Nakayama, F.S., Wong, J.H.M., Yang, T.I.M., Tree, J., Ludvigsson, C.M., Dayan, D. Tatovic, Single-cell RNA-seq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans. Front. Immunol. 14 (2023). https://doi.org/10.3389/fimmu.2023.1276255
[75] D. Tatovic, M.A. McAteer, J. Barry, A. Barrientos, K. Rodríguez Terradillos, I. Perera, E. Kochba, Y. Levin, M. Dul, S.A. Coulman, J.C. Birchall, C. von Ruhland, A. Howell, R. Stenson, M. Alhadj Ali, S.D. Luzio, G. Dunseath, W.Y. Cheung, G. Holland, K. May, J.R. Ingram, M.M.U. Chowdhury, F.S. Wong, R. Casas, C. Dayan, J. Ludvigsson, Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes, Immunother Adv 2 (2022) ltac002. https://doi.org/10.1093/immadv/ltac002
[76] D. Paithankar, B.H. Hwang, G. Munavalli, A. Kauvar, J. Lloyd, R. Blomgren, L. Faupel, T. Meyer, S. Mitragotri, Ultrasonic delivery of silica-gold nanoshells for photothermolysis of sebaceous glands in humans: Nanotechnology from the bench to clinic, J Control Release 206 (2015) 30-36. https://doi.org/10.1016/j.jconrel.2015.03.004
[77] R.S. Riley, E.S. Day, Gold nanoparticle-mediated photothermal therapy: Applications and opportunities for multimodal cancer treatment, Wiley Interdiscip Rev Nanomed Nanobiotechnol 9 (2017) e1449. https://doi.org/10.1002/wnan.1449
[78] Nanospectra Biosciences, Inc., A Pilot Study of AuroLase(tm) Therapy in Patients With Refractory and/or Recurrent Tumors of the Head and Neck, clinicaltrials.gov, 2016. https://clinicaltrials.gov/study/NCT00848042 (accessed June 29, 2025).
[79] Nanospectra Biosciences, Inc., A Pilot Study of AuroLase Therapy in Subjects with Primary and/or Metastatic Lung Tumors, clinicaltrials.gov, 2016. https://clinicaltrials.gov/study/NCT01679470 (accessed June 29, 2025).
[80] Nanospectra Biosciences, Inc., A Study of MRI/US Fusion Imaging and Biopsy in Combination with Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue, clinicaltrials.gov, 2021. https://clinicaltrials.gov/study/NCT02680535 (accessed June 29, 2025).
[81] D. Paithankar, B.H. Hwang, G. Munavalli, A. Kauvar, J. Lloyd, R. Blomgren, L. Faupel, T. Meyer, S. Mitragotri, Ultrasonic delivery of silica-gold nanoshells for photothermolysis of sebaceous glands in humans: Nanotechnology from the bench to clinic, J Control Release 206 (2015) 30-36. https://doi.org/10.1016/j.jconrel.2015.03.004
[82] M. Salimi, S. Mosca, B. Gardner, F. Palombo, P. Matousek, N. Stone, Nanoparticle-mediated photothermal therapy limitation in clinical applications regarding pain management, Nanomaterials (Basel) 12 (2022) 922. https://doi.org/10.3390/nano12060922
[83] M. Alle, G. Sharma, S.-H. Lee, J.-C. Kim, Next-generation engineered nanogold for multimodal cancer therapy and imaging: Clinical perspectives, J Nanobiotechnology 20 (2022) 222. https://doi.org/10.1186/s12951-022-01402-z
[84] S.E. Canfield, A.K. George, J.S. Jue, S.C. Lewis, M.S. Davenport, V.S. Tammisetti, M. Maruf, L.D. Borregalaes, Y. Kadria-Vili, J.A. Schwartz, J. West, N.J. Halas, A.R. Rastinehad, A multi-institutional study of magnetic resonance/ultrasound fusion-guided nanoparticle-directed focal therapy for prostate ablation, Journal of Urology 212 (2024) 862. https://doi.org/10.1097/JU.0000000000004222
[85] Nanospectra Biosciences, Inc., A Study of MRI/US Fusion Imaging and Biopsy in Combination with Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue, clinicaltrials.gov, 2023. https://clinicaltrials.gov/study/NCT04240639 (accessed June 29, 2025).
[86] A.N. Kharlamov, J.L. Gabinsky, Plasmonic photothermic and stem cell therapy of atherosclerotic plaque as a novel nanotool for angioplasty and artery remodeling, Rejuvenation Res 15 (2012) 222-230. https://doi.org/10.1089/rej.2011.1305
[87] A. Kharlamov, Plasmonic Photothermal Therapy of Flow-Limiting Atherosclerotic Lesions With Silica-Gold Nanoparticles: a First-in-Man Study, clinicaltrials.gov, 2021. https://clinicaltrials.gov/study/NCT01270139 (accessed June 29, 2025).
[88] A.N. Kharlamov, A.E. Tyurnina, V.S. Veselova, O.P. Kovtun, V.Y. Shur, J.L. Gabinsky, Silica-gold nanoparticles for atheroprotective management of plaques: Results of the NANOM-FIM trial, Nanoscale 7 (2015) 8003-8015. https://doi.org/10.1039/C5NR01050K
[89] A.P. Robinson, J.Z. Zhang, H.E. Titus, M. Karl, M. Merzliakov, A.R. Dorfman, S. Karlik, M.G. Stewart, R.K. Watt, B.D. Facer, J.D. Facer, N.D. Christian, K.S. Ho, M.T. Hotchkin, M.G. Mortenson, R.H. Miller, S.D. Miller, Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis, Scientific Reports 10 (2020) 1936. https://doi.org/10.1038/s41598-020-58709-w
[90] X. Huang, I.H. El-Sayed, X. Yi, M.A. El-Sayed, Gold nanoparticles: Catalyst for the oxidation of NADH to NAD(+), J Photochem Photobiol B 81 (2005) 76-83. https://doi.org/10.1016/j.jphotobiol.2005.05.010
[91] Clene Nanomedicine, A Phase 1 Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study of CNM-Au8 in Healthy Male and Female Volunteers, clinicaltrials.gov, 2019. https://clinicaltrials.gov/study/NCT02755870 (accessed June 30, 2025).
[92] K.M.S. Kanhai, R. Zuiker, W. Houghton, W.G. Kramer, K. McBride, M. Moerland, A. Dorfman, M. McGlothlin, M. Hotchkin, M. Mortenson, R. Etherington, G.J. Groeneveld, A first-in-human study in healthy subjects of the safety and pharmacokinetics of CNM-Au8, a suspension of catalytically active gold nanocrystals with remyelinating and neuroprotective properties, medRxiv 2023.05.11.23289871. https://doi.org/10.1101/2023.05.11.23289871
[93] Gylden Pharma Ltd, naNO-DENGUE: A Phase I Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T-Cell Priming Peptide Vaccine Against Dengue Virus in Healthy Adults in Switzerland, clinicaltrials.gov, 2022. https://clinicaltrials.gov/study/NCT04935801 (accessed June 30, 2025).
[94] Gylden Pharma Ltd, A Phase-I, Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 in Healthy Adults in Switzerland, clinicaltrials.gov, 2025. https://clinicaltrials.gov/study/NCT05113862 (accessed June 30, 2025).
[95] A. Miauton, R. Audran, J. Besson, H. Maby-El Hajjami, M. Karlen, L. Warpelin-Decrausaz, L. Sene, S. Schaufelberger, V. Faivre, M. Faouzi, M.-A. Hartley, F. Spertini, B. Genton, Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: A double-blind, randomized, vehicle-controlled, phase 1 study, EBioMedicine 99 (2024) 104922. https://doi.org/10.1016/j.ebiom.2023.104922
[96] J. Besson, R. Audran, M. Karlen, A. Miauton, H.M.-E. Hajjami, L. Warpelin-Decrausaz, L. Sene, S. Schaufelberger, V. Faivre, M. Faouzi, M.-A. Hartley, F. Spertini, B. Genton, A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: A double-blind, randomized, phase 1 study in Switzerland, BMC Infect Dis 25 (2025) 472. https://doi.org/10.1186/s12879-025-10844-3